Management of relapsing Plasmodium vivax malaria

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 10, 2016, Pages 885-900

  Chu, Cindy S ^a,b   White, Nicholas J ^b,c  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

8 aminoquinoline; anti malarial efficacy; chloroquine; glucose 6 phosphate dehydrogenase deficiency; Plasmodium vivax; Plasmodium vivax relapse; Plasmodium vivax treatment; primaquine; radical cure; review

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MALARIA VACCINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; RIFAMPICIN; TAFENOQUINE; ANTIMALARIAL AGENT;

ANEMIA; ANTIMALARIAL DRUG RESISTANCE; COMORBIDITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; GEOGRAPHIC DISTRIBUTION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; INFECTION RATE; MALNUTRITION; METHEMOGLOBINEMIA; MORBIDITY; NONHUMAN; PATIENT COMPLIANCE; PERINATAL PERIOD; PLASMODIUM VIVAX MALARIA; PREGNANCY; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; ISOLATION AND PURIFICATION; LIVER; MALARIA, VIVAX; PARASITOLOGY; PLASMODIUM VIVAX; PRACTICE GUIDELINE; RECURRENT DISEASE;

ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; LIVER; MALARIA, VIVAX; PLASMODIUM VIVAX; PRACTICE GUIDELINES AS TOPIC; PRIMAQUINE; RECURRENCE;

EID: 84987724376     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1220304     Document Type: Review

References (202)

1. S.I.Hay, C.A.Guerra, A.J.Tatem, et al. The global distribution and population at risk of malaria:past, present, and future. Lancet Infect Dis. 2004;4(6):327–336.
2. P.W.Gething, I.R.F.Elyazar, C.L.Moyes, et al. A long neglected world malaria map:Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6(9):e1814.
3. K.E.Battle, M.S.Karhunen, S.Bhatt, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13(1):144.• This paper provides a global map of relapse patterns.
4. J.C.P.Rodríguez, G.Á.Uribe, R.M.Araújo, et al. Epidemiology and control of malaria in Colombia. Mem Inst Oswaldo Cruz. 2011;106:114–122.
5. T.H.Katsuragawa, L.H.S.Gil, M.S.Tada, et al. The dynamics of transmission and spatial distribution of malaria in riverside areas of Porto Velho, Rondônia, in the amazon region of Brazil. PLoS One. 2010;5(2):e9245.
6. K.E.Battle, P.W.Gething, I.R.F.Elyazar, et al. The global public health significance of Plasmodium vivax. In:S.I.Hay, R.N.Price, J.K.Baird, editor. Advances in Parasitology. Oxford:Academic Press; 2012. p. 1–257.
7. G.R.Coatney Relapse in malaria - an enigma. J Parasitol. 1976;62(1):3–9.
8. P.C.Korteweg. Klinische obersvaties over malaria in den winter van 1901-’02, herinneringsbundel voor Prof. Rosenstein. Leiden. 1902;263–281.
9. P.T.Manson. Experimental malaria:recurrence after nine months. Br Med J. 1901;2(2115):77.
10. W.Yorke. Further observations on malaria made during treatment of general paralysis. Trans R Soc Trop Med Hyg. 1926;19(3):108–131.
11. W.C.Cooper, G.R.Coatney, D.S.Ruhe. Studies in human malaria V. homologous strain superinfection during latency in subjects with sporozoite-induced vivax malaria (St. Elizabeth strain). Am J Epidemiol. 1947;46(1):141–148.
12. N.H.Swellengrebel, A.De Buck. Malaria in the Netherlands. Amsterdam:Scheltema & Holkema; 1938.
13. G.R.Coatney, W.C.Cooper, M.D.Young. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J Natl Malar Soc. 1950;9(4):381–396.
14. M.Ciuca, L.Ballif, M.Chelarescu-Vieru. Immunity in malaria. Trans R Soc Trop Med Hyg. 1934;27(6):619–622.
15. S.P.James, W.D.Nicol, P.G.Shute. Clinical and parasitological observations on induced malaria. Proc R Soc Med. 1936;29(8):879–894.
16. M.F.Boyd. A review of studies on immunity to vivax malaria. J Natl Malar Soc. 1947;6(1):12–31.
17. N.J.White. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10(1):297.•• This paper describes the different relapse patterns and provides an explanation for the periodicity of P. vivax relapse.
18. C.M.Whorton, E.YountJr., R.JonesJr, et al. The Chesson strain of Plasmodium vivax malaria; clinical aspects. J Infect Dis. 1947;80(3):237–249.
19. A.S.Alving, J.Arnold, D.H.Robinson. Mass therapy of subclinical vivax malaria with primaquine. J Am Med Assoc. 1952;149(17):1558–1562.
20. T.Adak, V.P.Sharma, V.S.Orlov. Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg. 1998;59(1):175–179.
21. W.A.Krotoski, W.E.Collins, R.S.Bray, et al. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg. 1982;31(6):1291–1293.
22. S.Looareesuwan, N.J.White, S.Chittamas, et al. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet. 1987;2(8567):1052–1055.
23. C.F.A.Craig. Study of latent and recurrent malarial infection and the significance of intracorpuscular conjugation in the Malarial plasmodia. J Infect Dis. 1907;4(1):108–140.
24. G.D.Shanks, N.J.White. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis. 2013;13(10):900–906.
25. M.Imwong, G.Snounou, S.Pukrittayakamee, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195(7):927–933.
26. M.Imwong, M.E.Boel, W.Pagornrat, et al. The first Plasmodium vivax relapses of life are usually genetically homologous. J Infect Dis. 2012;205(4):680–683.
27. J.A.Cattani. The epidemiology of malaria in Papua New Guinea. Hum Biol Papua New Guinea Small Cosm. 1992;35(1):302–312.
28. C.Luxemburger, K.L.Thwai, N.J.White, et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg. 1996;90(2):105–111.
29. M.Karyana, L.Burdarm, S.Yeung, et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J. 2008;7:148.
30. D.K.Kochar, G.S.Tanwar, P.C.Khatri, et al. Clinical features of children hospitalized with malaria — a study from Bikaner, northwest India. Am J Trop Med Hyg. 2010;83(5):981–989.
31. J.Carmona, R.Scátegui, A.Correa. Malaria vivax en niños:aspectos clínicos y respuesta a la cloroquina. Colomb Med. 2008;39(4):364–377.
32. F.H.Nosten, R.M.McGready, J.A.Simpson, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet. 1999;354(9178):546–549.
33. M.E.Boel, M.J.Rijken, T.Leenstra, et al. Malaria in the post-partum period; a prospective cohort study. Speybroeck N, ed. PLoS One. 2013;8(3):e57890.
34. B.J.Brabin, C.Piper. Anaemia- and malaria-attributable low birthweight in two populations in Papua New Guinea. Ann Hum Biol. 1997;24(6):547–555.
35. C.Luxemburger, R.M.McGready, A.Kham, et al. Effects of malaria during pregnancy on infant mortality in an area of low malaria transmission. Am J Epidemiol. 2001;154(5):459–465.
36. K.A.Moore, J.A.Simpson, M.K.Paw, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies:an observational study. Lancet Infect Dis. 2016;3099(15):1–8.
37. E.Tjitra, N.M.Anstey, P.Sugiarto, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria:a prospective study in Papua, Indonesia. PLoS Med. 2008;5(6):e128.
38. J.R.Poespoprodjo, W.Fobia, E.Kenangalem, et al. Vivax malaria:a major cause of morbidity in early infancy. Clin Infect Dis. 2009;48:1704–1712.
39. M.L.Gatton. Costs to the patient for seeking malaria care in Myanmar. Acta Trop. 2004;92(3):173–177.
40. T.N.Williams, K.Maitland, L.Phelps, et al. Plasmodium vivax:a cause of malnutrition in young children. QJM. 1997;90(12):751–757.
41. G.Lee, P.Yori, M.P.Olortegui, et al. Comparative effects of vivax malaria, fever and diarrhoea on child growth. Int J Epidemiol. 2012;41(2):531–539.
42. N.M.Douglas, N.M.Anstey, P.A.Buffet, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135.
43. S.Langford, N.M.Douglas, D.A.Lampah, et al. Plasmodium malariae infection associated with a high burden of anemia:a hospital-based surveillance study. PLoS Negl Trop Dis. 2015;9(12):1–16.• This paper shows the contribution of different species of malaria to anemia in young children in settings where transmission and relapse rates are high.
44. M.Echeverri, A.Tobon, G.Alvarez, et al. Clinical and laboratory findings of Plasmodium vivax malaria in Colombia, 2001. Rev Inst Med Trop Sao Paulo. 2003;45(1):29–34.
45. M.J.Rijken, R.M.McGready, M.E.Boel, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis. 2012;12(1):75–88.
46. D.H.Hamer, M.P.Singh, B.J.Wylie, et al. Burden of malaria in pregnancy in Jharkhand State, India. Malar J. 2009;8:210.
47. M.L.Dreyfuss, R.J.Stoltzfus, J.B.Shrestha, et al. Hookworms, malaria and vitamin A deficiency contribute to anemia and iron deficiency among pregnant women in the plains of Nepal. J Nutr. 2000;130(10):2527–2536.
48. J.R.Poespoprodjo, W.Fobia, E.Kenangalem, et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008;46(9):1374–1381.
49. D.Nega, D.Dana, T.Tefera, et al. Prevalence and predictors of asymptomatic malaria parasitemia among pregnant women in the rural surroundings of Arbaminch Town, South Ethiopia. PLoS One. 2015;10(4):4–9.
50. S.K.Bhattacharya, D.Sur, S.Dutta, et al. Vivax malaria and bacteraemia:a prospective study in Kolkata, India. Malar J. 2013;12(1):1.
51. B.Genton, V.D’Acremont, L.Rare, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children:a prospective cohort study from Papua New Guinea. PLoS Med. 2008;5(6):e127.
52. M.A.A.Alexandre, C.O.Ferreira, A.M.Siqueira, et al. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis. 2010;16(10):1611–1614.
53. E.F.C.Lança, B.M.L.Magalhães, S.Vitor-Silva, et al. Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the brazilian amazon. PLoS One. 2012;7(4):e35406.
54. H.Mahgoub, G.I.Gasim, I.R.Musa, et al. Severe Plasmodium vivax malaria among Sudanese children at new halfa hospital, Eastern Sudan. Parasit Vectors. 2012;5(1):154.
55. S.Shaikh, H.Memon, B.Iohano, et al. Severe disease in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern Pakistan. Malar J. 2012;11:144.
56. V.K.Gehlawat, V.Arya, J.S.Kaushik, et al. Clinical spectrum and treatment outcome of severe malaria caused by Plasmodium vivax in 18 children from northern India. Pathog Glob Health. 2013;107(4):210–214.
57. V.Jain, A.Agrawal, N.Singh. Malaria in a tertiary health care facility of central India with special reference to severe vivax:implications for malaria control. Pathog Glob Health. 2013;107(6):299–304.
58. B.A.Rahimi, A.Thakkinstian, N.J.White, et al. Severe vivax malaria:a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014;13:481.
59. M.V.G.Lacerda, M.P.G.Mourão, M.A.A.Alexandre, et al. Understanding the clinical spectrum of complicated Plasmodium vivax malaria:a systematic review on the contributions of the Brazilian literature. Malar J. 2012;11(1):12.
60. A.M.Quispe, E.Pozo, E.Guerrero, et al. Plasmodium vivax hospitalizations in a monoendemic malaria region:severe vivax malaria? Am J Trop Med Hyg. 2014;91(1):11–17.
61. V.B.Kute, H.L.Trivedi, A.V.Vanikar, et al. Plasmodium vivax malaria-associated acute kidney injury, India, 2010-2011. Emerg Infect Dis. 2012;18(5):842–845.
62. A.B.S.Zubairi, S.Nizami, A.Raza, et al. Severe Plasmodium vivax malaria in Pakistan. Emerg Infect Dis. 2013;19(11):1851–1854.
63. D.K.Kochar, A.Das, A.Kochar, et al. A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India. J Vector Borne Dis. 2014;51(3):200–210.
64. K.C.Nayak, S.Kumar, B.K.Gupta, et al. Clinical and histopathological profile of acute renal failure caused by falciparum and vivax monoinfection:an observational study from Bikaner, northwest zone of Rajasthan, India. J Vector Borne Dis. 2014;51(March):40–46.
65. A.M.Siqueira, M.V.G.Lacerda, B.M.L.Magalhães, et al. Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India. BMC Med. 2015;13(October):57.
66. World Health Organization. Global Malaria Progamme. Control and elimination of Plasmodium vivax malaria – A technical brief. Geneva:World Health Organization; 2015.
67. H.Most, I.M.London, C.A.Kane, et al. Chloroquine for treatment of acute attacks of vivax malaria. J Am Med Assoc. 1946;131(12):963–967.
68. C.Luxemburger, M.van Vugt, S.Jonathan, et al. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg. 1999;93(4):433–438.
69. I.Sutanto, B.Tjahjono, H.Basri, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother. 2013;57(3):1128–1135.
70. I.Betuela, A.Rosanas-Urgell, B.Kiniboro, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis. 2012;206(11):1771–1780.• This study prospectively measured the incidence of new P. vivax infections and determined the burden of relapse in a high-transmission setting.
71. R.W.Berliner, D.P.Earle, J.V.Taggart, et al. Studies on the chemotherapy of the human malarias. VI the physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Investig. 1948;27(3Part 2):98–107.
72. D.Projean, B.Baune, R.Farinotti, et al. In vitro metabolism of chloroquine:identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31(6):748–754.
73. S.J.Lee, R.M.McGready, C.Fernandez, et al. Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol. 2008;64(10):987–992.
74. S.Pukrittayakamee, J.Tarning, P.Jittamala, et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 2014;58(6):3354–3359.
75. E.E.Essien, G.C.Afamefuna. Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication. Clin Chem. 1982;28(5):1148–1152.
76. N.J.White, K.D.Miller, F.C.Churchill, et al. Chloroquine treatment of severe malaria in children. N Engl J Med. 1988;319(23):1493–1500.
77. R.W.Prouty, K.Kuroda. Spectrophotometric determination and distribution of chloroquine in human tissues. J Lab Clin Med. 1958;52:477.
78. K.Kuroda. Detection and distribution of chloroquine metabolites in human tissues. J Pharmacol Exp Ther. 1962;137(2):156–161.
79. M.Rubin, H.N.Bernstein, N.J.Zvaifler. Studies on the pharmacology of chloroquine, recommendations for the treatment of chloroquine retinopathy. JAMA J Am Med Assoc. 1963;70:474–481.
80. J.K.Baird, B.Leksana, S.Masbar, et al. Whole blood chloroquine concentrations with Plasmodium vivax infection in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1997;56(6):618–620.
81. W.R.J.Taylor, N.J.White. Antimalarial drug toxicity:a review. Drug Saf. 2004;27(1):25–61.
82. M.Whitby, G.Wood, J.R.Veenendaal, et al. Chloroquine resistant Plasmodium vivax. Lancet. 1989;334(8676):1395.
83. K.H.Rieckmann, D.R.Davis, D.C.Hutton. Plasmodium vivax resistance to chloroquine? Lancet. 1989;2(8673):1183–1184.
84. J.K.Baird, H.Basri, M.J.Bangs, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991;44(5):547–552.
85. P.L.Garavelli, E.Corti. Chloroquine resistance in Plasmodium vivax:the first case in Brazil. Trans R Soc Trop Med Hyg. 1992;86(2):128.
86. P.K.Myat, O.Myint, L.Myint, et al. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg. 1993;87(6):687.
87. K.Van Den Abbeele, E.Van Den Enden, J.Van Den Ende. Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India. Ann Soc Belge Med Trop. 1995;75:73–74.
88. E.J.Phillips, J.S.Keystone, K.C.Kain. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis. 1996;23(5):1171–1173.
89. J.Soto, J.Toledo, P.Gutierrez, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg. 2001;65(2):90–93.
90. T.K.Ruebush, J.Zegarra, J.Cairo, et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg. 2003;69(5):548–552.
91. R.Leang, A.Barrette, D.M.Bouth, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013;57(2):818–826.
92. H.Teka, B.Petros, L.Yamuah, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220.
93. A.P.Phyo, K.M.Lwin, R.N.Price, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax Malaria in Thailand:a randomized controlled trial. Clin Infect Dis. 2011;53(10):977–984.
94. M.J.Rijken, M.E.Boel, B.Russell, et al. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malar J. 2011;10:113.
95. A.Añez, M.Moscoso, Á.Laguna, et al. Resistance of infection by Plasmodium vivax to chloroquine in Bolivia. Malar J. 2015;14:261.
96. S.Shalini, S.Chaudhuri, P.L.Sutton, et al. Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India. Malar J. 2014;13(1):129.
97. S.Ganguly, P.Saha, S.K.Guha, et al. In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother. 2013;57(3):1246–1251.
98. T.Waqar, A.Khushdil, K.Haque. Efficacy of chloroquine as a first line agent in the treatment of uncomplicated malaria due to Plasmodium vivax in children and treatment practices in Pakistan:a pilot study. J Pak Med Assoc. 2016;66(1):30–33.
99. H.Liu, H.Yang, L.Tang, et al. Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008–2013. Malar J. 2014;13(1):364.
100. P.D.Thuan, N.T.N.Ca, P.V.Toi, et al. A randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam. Am J Trop Med Hyg. 2016;94:879–885.
101. K.Congpuong, W.Satimai, A.Sujariyakul, et al. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010. J Vector Borne Dis. 2011;48(4):190–196.
102. C.Amaratunga, S.Sreng, S.Mao, et al. Chloroquine remains effective for treating Plasmodium vivax malaria in Pursat province, Western Cambodia. Antimicrob Agents Chemother. 2014;58(10):6270–6272.
103. M.R.Costa, F.E.Martinez-, J.L.Vieira. Chloroquine- resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 2007;13(7):7–8.
104. A.Ríos, G.Álvarez, S.Blair. Diez años de eficacia terapéutica de la cloroquina en malaria no complicada por Plasmodium vivax, Turbo, Antioquia, años 2002 y 2011. Biomédica. 2013;33:429–438.
105. J.-P.Guthmann, A.Pittet, A.Lesage, et al. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Heal. 2008;13(1):91–98.
106. V.I.Carrara, K.M.Lwin, A.P.Phyo, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai–Myanmar border, 1999–2011:an observational study. PLoS Med. 2013;10(3):e1001398.
107. A.Ratcliff, H.Siswantoro, E.Kenangalem, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101(4):351–359.
108. J.K.Baird, J.D.Maguire, R.N.Price. Diagnosis and treatment of Plasmodium vivax malaria. Adv Parasitol. 2012;80:203–270.
109. J.Ursing, S.Eksborg, L.Rombo, et al. Chloroquine is grossly under dosed in young children with malaria:implications for drug resistance. PLoS One. 2014;9(1):6–11.
110. E.C.Duarte, L.W.Pang, L.C.Ribeiro, et al. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg. 2001;65(5):471–476.
111. R.N.Price, L.von Seidlein, N.Valecha, et al. Global extent of chloroquine-resistant Plasmodium vivax:a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):982–991.
112. S.Pukrittayakamee, C.Viravan, P.Charoenlarp, et al. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother. 1994;38(3):511–514.
113. S.Looareesuwan, P.Wilairatana, R.Glanarongran, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg. 1999;93(6):637–640.
114. S.Pukrittayakamee, A.Chantra, J.A.Simpson, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000;44(6):1680–1685.
115. G.T.Phan, P.J.de Vries, B.Q.Tran, et al. Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int Heal. 2002;7(10):858–864.
116. U.Silachamroon, S.Krudsood, S.Treeprasertsuk, et al. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg. 2003;69S(1):14–18.
117. S.Krudsood, N.Tangpukdee, P.Wilairatana, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg. 2008;78(5):736–740.
118. P.Wilairatana, U.Silachamroon, S.Krudsood, et al. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg. 1999;61(6):973–977.
119. H.Karunajeewa, I.Müeller, M.Senn, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359(24):2545–2557.
120. A.R.Hasugian, H.L.Purba, E.Kenangalem, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine:superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007;44(8):1067–1074.
121. A.P.Pasaribu, W.Chokejindachai, C.Sirivichayakul, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis. 2013;208(11):1906–1913.
122. A.Ratcliff, H.Siswantoro, E.Kenangalem, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia:an open-label randomised comparison. Lancet. 2007;369(9563):757–765.
123. S.Krudsood, N.Tangpukdee, S.Muangnoicharoen, et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol. 2007;45(2):111–114.
124. A.M.Yohannes, A.Teklehaimanot, Y.Bergqvist, et al. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg. 2011;84(1):137–140.
125. G.R.Awab, S.Pukrittayakamee, M.Imwong, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan:an open randomized, non-inferiority, trial. Malar J. 2010;9:105.
126. Y.Poravuth, D.Socheat, R.Rueangweerayut, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria:a randomized, double-blind, non-inferiority trial. PLoS One. 2011;6(1):e14501.
127. J.Carmona-Fonseca, O.M.Agudelo-García, E.Arango-Flórez. Therapeutic efficacy and adverse events of treatments for vivax and falciparum malaria in pregnant women in the regions of Uraba and Alto San Jorge, Colombia, 2008-2011. Rev Colomb Obstet Ginecol. 2013;64(1):27–37.
128. J.R.Poespoprodjo, W.Fobia, E.Kenangalem, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One. 2014;9(1):e84976.
129. J.Tarning, P.Thana, A.P.Phyo, et al. Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand. CPT Pharmacometrics Syst Pharmacol. 2014;3(April):e132.
130. J.D.Maguire, Krisin, H.Marwoto, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis. 2006;2197:1067–1072.
131. J.A.Sinton. Studies in malaria, with special reference to treatment. Part XVI. The relationship of season to cure rate. Indian J Med Res. 1930;17(3):793–814.
132. G.W.Mihaly, S.A.Ward, G.Edwards, et al. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985;19(6):745–750.
133. S.Ganesan, B.L.Tekwani, R.Sahu, et al. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009;241(1):14–22.
134. B.S.Pybus, J.C.Sousa, X.Jin, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11(1):1.
135. P.S.Fasinu, B.L.Tekwani, N.D.P.D.Nanayakkara, et al. Enantioselective metabolism of primaquine by human CYP2D6. Malar J. 2014;13(1):507.
136. S.Agarwal, U.R.Gupta, R.C.Gupta, et al. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites. 1;-I effect on reduced glutathione, methemoglobin content and release of hemoglobin. Biochem Pharmacol. 1988;37(24):4605–4609.
137. B.Avula, B.L.Tekwani, N.D.Chaurasiya, et al. Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13 C stable isotope labeling. J Mass Spectrom. 2013;48:276–285.
138. N.P.D.Nanayakkara, B.L.Tekwani, B.Herath, et al. Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers. Antimicrob Agents Chemother. 2014;58(8):4737–4744.
139. B.T.Cuong, V.Q.Binh, B.Dai, et al. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol. 2006;61(6):682–689.
140. A.S.Alving, J.Arnold, R.S.Hockwald, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46(2):301–306.
141. B.Hanboonkunupakarn, E.A.Ashley, P.Jittamala, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects. Antimicrob Agents Chemother. 2014;58(12):7340–7346.
142. P.Jittamala, S.Pukrittayakamee, E.A.Ashley, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59(1):505–513.
143. G.Edwards, C.S.McGrath, S.A.Ward, et al. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol. 1993;35:193–198.
144. K.Na-Bangchang, J.Karbwang, R.Ubalee, et al. Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials. Eur J Drug Metab Pharmacokinet. 2000;25(3–4):171–178.
145. M.Nacher, A.Stefani, C.Basurko, et al. The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana. Malar J. 2013;12(1):367.
146. N.Khantikul, P.Butraporn, H.S.Kim, et al. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Heal Popul Nutr. 2009;27(1):4–13.
147. R.Takeuchi, S.Lawpoolsri, M.Imwong, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J. 2010;9:308.
148. W.Maneeboonyang, S.Lawpoolsri, S.Puangsa-Art, et al. Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health. 2011;42(1):9–18.
149. K.P.Grietens, V.Soto, A.Erhart, et al. Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the peruvian amazon. Am J Trop Med Hyg. 2010;82(6):1017–1023.
150. T.Leslie, M.A.Rab, H.Ahmadzai, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg. 2004;98(3):168–173.
151. C.B.Clayman, J.Arnold, R.S.Hockwald, et al. Toxicity of primaquine in Caucasians. J Am Med Assoc. 1952;149(17):1563–1568.
152. J.Recht, E.A.Ashley, N.J.White. Safety of 8-aminoquinoline antimalarial medicines. Geneva:World Health Organization Global Malaria Programme; 2014.•• This is an exhaustive review of the safety of 8-aminoquinolines and compiles all known serious adverse events associated with primaquine into concise summaries and tables.
153. J.E.Hansen, E.Cleve, F.Pruitt. Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine. Am J Med Sci. 1954;227(1):9–12.
154. D.R.Hill, J.K.Baird, M.E.Parise, et al. Primaquine:report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75(3):402–415.
155. E.A.Ashley, J.Recht, N.J.White. Primaquine:the risks and the benefits. Malar J. 2014;13(1):418.
156. R.S.Hockwald, J.Arnold, C.B.Clayman, et al. Toxicitiy of Primaquine in Negroes. J Am Med Assoc. 1952;149(17):1568–1570.
157. R.E.Howes, M.Dewi, F.B.Piel, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418.• This paper provides a global map of G6PD deficiency.
158. W.M.Monteiro, J.P.Moura-Neto, J.Recht, et al. Fatal primaquine-induced hemolysis in a patient with Plasmodium vivax malaria and G6PD A- variant in the Brazilian amazon. Clin Infect Dis. 2016;62(9):1188.
159. J.Arnold, A.S.Alving, R.S.Hockwald, et al. The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J Lab Clin Med. 1954;44(3):429–438.
160. A.S.Alving, C.F.Johnson, A.R.Tarlov, et al. Mitigation of the haemolytic effect of primaquine and enhancement of its action against the exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull World Health Organ. 1960;22:621–631.
161. S.Vivona, G.J.Brewer, M.Conrad, et al. The concurrent weekly administration of chloroquine and primaquine for the prevention of Korean vivax malaria. Bull World Heal Organ. 1961;25:267–269.
162. S.Kheng, S.Muth, W.R.J.Taylor, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13:203.
163. K.Burgoine, G.Bancone, F.H.Nosten. The reality of using primaquine. Malar J. 2010;9(1):376.
164. D.Bunnag, J.Karbwang, A.Thanavibul, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg. 1994;88(2):218–219.
165. K.Buchachart, S.Krudsood, P.Singhasivanon, et al. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Heal. 2001;32(4):720–726.
166. N.J.Gogtay, S.Desai, K.D.Kamtekar, et al. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol. 1999;93(8):809–812.
167. D.D.Rajgor, N.J.Gogtay, V.S.Kadam, et al. Antirelapse efficacy of various primaquine regimens for Plasmodium vivax. Malar Res Treat. 2014;2014:347018.
168. M.Rowland, N.Durrani. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg. 1999;93(6):641–643.
169. A.Valibayov, F.Abdullayev, S.Mammadov, et al. Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan. Acta Trop. 2003;88(1):99–102.
170. P.Van den Eede, V.E.Soto-Calle, C.Delgado, et al. Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients:results of a 1-year prospective cohort study. PLoS One. 2011;6(1):e16257.
171. J.Carmona-Fonseca, A.Maestre. Prevention of Plasmodium vivax malaria recurrence:efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop. 2009;112(2):188–192.
172. J.Carmona-Fonseca. Malaria vivax en niños:recurrencias con dosis total estándar de primaquina administrada durante 3 frente a 7 días. Iatreia. 2010;23(1):10–20.
173. N.P.Abdon, A.Y.das Neves Pinto, R.do Socorro Uchôa das Silva, et al. Avaliação da resposta aos esquemas de tratamento reduzidos para malária vivax. Rev Soc Bras Med Trop. 2001;34(4):343–348.
174. A.K.Yeshiwondim, A.H.Tekle, D.O.Dengela, et al. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop. 2010;113(2):105–113.
175. P.Muhamad, R.Ruengweerayut, W.Chacharoenkul, et al. Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malar J. 2011;10(1):44.
176. S.Durand, C.Cabezas, A.G.Lescano, et al. Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon basin of Peru. Am J Trop Med Hyg. 2014;91:18–26.
177. J.R.Kim, A.Nandy, A.K.Maji, et al. Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. PLoS One. 2012;7(7):e39645.
178. G.K.John, N.M.Douglas, L.von Seidlein, et al. Primaquine radical cure of Plasmodium vivax:a critical review of the literature. Malar J. 2012;11(1):280.•• This article is a thorough review of primaquine studies which examines the use of G6PD testing before study inclusion.
179. S.Ganguly, P.Saha, S.K.Guha, et al. Recurrence pattern of P. vivax malaria following treatment with chloroquine either alone or in combination with primaquine in Urban Kolkata, India. Int J Recent Sci Res. 2014;5(6):1046–1049.
180. N.V.H.Dao, B.T.Cuong, N.D.Ngoa, et al. Vivax malaria:preliminary observations following a shorter course of treatment with artesunate plus primaquine. Trans R Soc Trop Med Hyg. 2007;101(6):534–539.
181. Pukrittayakamee S, Imwong M, Chotivanich KT, Singhasivanon P, Day NPJ, White NJ. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg. 2010;82(4):542–547.
182. T.Leslie, I.Mayan, N.Mohammed, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One. 2008;3(8):e2861.
183. World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva:WHO Press; 2015.
184. World Health Organization. World Malaria Report 2015. Geneva:World Health Organization; 2015.
185. M.Salehi, F.Rakhshani. Relapse rate of vivax malaria with different regimens of antirelapse treatment in Iran:a field evaluation. J Med Sci. 2005;5(2):125–129.
186. L.Rombo, G.Edwards, S.A.Ward, et al. Seven patients with relapses of Plasmodium vivax or P. ovale despite primaquine treatment. Trop Med Parasitol. 1987;38(1):49–50.
187. S.Looareesuwan, K.Buchachart, P.Wilairatana, et al. Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol. 1997;91(8):939–943.
188. D.J.Na, J.D.Han, D.Y.Cha, et al. Imported tertian malaria resistant to primaquine. Korean J Intern Med. 1999;14(2):86–89.
189. J.M.Spudick, L.S.Garcia, D.M.Graham, et al. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin Microbiol. 2005;43(2):978–981.
190. R.S.Pedro, L.Guaraldo, D.P.Campos, et al. Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil. Malar J. 2012;11(1):245.
191. B.S.Pybus, S.R.Marcsisin, X.Jin, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12(1):212.
192. A.E.Becker, A.Kleinman. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1380–1381.
193. R.P.Brueckner, K.C.Lasseter, E.T.Lin, et al. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58(5):645–649.
194. D.S.Walsh, P.Wilairatana, D.B.Tang, et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis. 2004;39:1095–1103.
195. S.Kitchener, P.Nasveld, M.D.Edstein. Short report:tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg. 2007;76(3):494–496.
196. A.Llanos-Cuentas, M.V.G.Lacerda, R.Rueangweerayut, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE):a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049–1058.•• This is the first large trial to measure the efficacy of single-dose tafenoquine against P. vivax relapses.
197. S.R.Marcsisin, J.C.Sousa, G.A.Reichard, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity:implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13(2):1–9.
198. P.L.St Jean, Z.Xue, N.Carter, et al. Tafenoquine treatment of Plasmodium vivax malaria:suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2b DETECTIVE trial. Malar J. 2016;15(1):97.
199. N.J.White. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002;18(10):458–464.
200. J.C.Cutts, R.Powell, P.A.Agius, et al. Immunological markers of Plasmodium vivax exposure and immunity:a systematic review and meta-analysis. BMC Med. 2014;12(1):1–20.
201. J.W.Bennett, A.Yadava, D.Tosh, et al. Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults:safety, immunogenicity, and efficacy. PLoS Negl Trop Dis. 2016;10(2):e0004423.
202. World Health Organization. Tables of malaria vaccine programs globally. Geneva:World Health Organization; 2015.